Sampling, matrices and the 3Rs at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

8 organizations at EBF 2026 present work in microsampling, matrices and the 3rs: 4 CROs and suppliers, 3 drug developers and 1 university or other organization. Between them they bring 25 presentations to the program. Most represented: Roche (9 on the program), Charles River Laboratories (5 on the program), Resolian (3 on the program). As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–8 of 8 organizations

Organization	EBF 2026 Attendance
Roche Basel, Switzerland
roche.com Pharma Pharmaceutical and diagnostics group developing medicines in oncology, immunology, neuroscience and ophthalmology, alongside its Roche Diagnostics business.	Talk Tue Nov 17 11:30–11:50am Part of Session 2: Smarter Workflows: From Implementation to Scientific Confidence Clinical Speed meets GLP Rigor: Upgrading an IVD Immunoanalyzer for High-Throughput PK/PD Analysis in a Bioanalytical Laboratory - Lessons Learnt Automation & AI · Ligand binding Talk Tue Nov 17 2:40–3pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics LC-MS Bioanalysis of Lipid Conjugated siRNAs: Analytical Challenges and Novel Approaches New modalities · LC–MS Talk Tue Nov 17 5:20–5:40pm Part of Session 7: BM CoU in practice Navigating Soluble Biomarker Complexity: Challenges, Assay Strategy, and Case Studies Biomarkers Talk Wed Nov 18 9–9:20am Part of Session 10: Bioanalysis Beyond Conventional Matrices From First-in-Human to Multi-Site Trials: Practical Bioanalytical Strategies to Preserve CSF Pharmacokinetic Data for Highly Adsorptive Molecules Sampling Talk Wed Nov 18 9:20–9:40am Part of Session 12: Assay life cycle Assay Lifecycle in Practice: Strategic Stewardship, Change Control, and Revalidation Case Studies Regulation Talk Wed Nov 18 9:40–10am Part of Session 10: Bioanalysis Beyond Conventional Matrices Operationalizing Unstable Biomarkers: How Biosample Operations and Bioanalysis Enable Successful Scale-Up from Single-Site to Multi-Site Clinical Trials Biomarkers · Sampling Talk Wed Nov 18 5–5:20pm Part of Workshop 10: ADA - Adaptive Tier Overcoming the 3-Tier ADA Testing Paradigm via Mechanistic Assay Understanding Immunogenicity Talk Thu Nov 19 9:20–9:40am Part of Session 16: Protein MS tech 1 A Multiplexed LC-MS/MS Strategy for the Simultaneous Quantification of a Transgene Protein and its Endogenous Counterpart in a Gene Therapy Program. LC–MS Talk Thu Nov 19 11:30–11:50am Part of Session 20: Pushing the Limits of Sensitivity and Multiplexing in Bioanalysis Navigating High-Plex Profiling and Targeted Quantification in Drug Development Biomarkers
Charles River Laboratories Wilmington, Massachusetts	◇Sponsor
criver.com Bioanalytical CROsSponsor Contract research organization providing discovery, safety assessment and bioanalysis services for drug developers.	Talk Tue Nov 17 12:10–12:30pm Part of Session 3: Vaccines Harmonizing Validation of Vaccine Immunogenicity Assays: A Fit-for-Purpose Framework for Quantitative and Semi-Quantitative Methods Vaccines · Immunogenicity Talk Tue Nov 17 2:20–2:40pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows Transition from Duplicate to Singlicate ADA Testing: A Retrospective Evaluation of Clinical Immunogenicity Data Immunogenicity · Sampling Talk Tue Nov 17 5–5:20pm Part of Session 8: Pharma CRO Analytical Challenges of Gas Shuttling Nanomedicine: A case study of Inter-CRO Transfer of a Bioanalytical Method for Complex Modalities New modalities Talk Wed Nov 18 12–12:20pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 Rethinking In-Study Cut Point Application for siRNA Immunogenicity Assessment When False Positive Rates Fall Outside the Conventional Range Immunogenicity · New modalities Talk Thu Nov 19 12:10–12:30pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Decoding ADC Complexity: Bioanalytical LC-MS Approaches and application to preclinical and clinical studies New modalities · LC–MS
Resolian Malvern, Pennsylvania	◇Sponsor
resolian.com Bioanalytical CROsSponsor Bioanalytical and CMC analytical CRO formed from LGC's drug development business and Alliance Pharma, with labs in the US, UK, China and Australia.	Talk Tue Nov 17 2:40–3pm Part of Session 6: Biosimilars Demonstrating Antigenic Equivalence Across Biosimilars and Reference Products: ADA and NAb Assay Validation Strategies Through Real-World Case Studies Immunogenicity Talk Wed Nov 18 9:20–9:40am Part of Session 10: Bioanalysis Beyond Conventional Matrices Bioanalytical Challenges of PK Assessment in Nasal Mucosal Lining Fluid for a Novel Antiviral Therapeutic Sampling Talk Thu Nov 19 9–9:20am Part of Session 16: Protein MS tech 1 Extending the Sensitivity of a Hybrid LC-MS/MS Assay for PAD2 and PAD4 Through Microflow Chromatography LC–MS
Labcorp Burlington, North Carolina	◇Sponsor
labcorp.com Bioanalytical CROsSponsor Laboratory services company whose drug development unit runs central lab, bioanalysis and early development services.	Talk Tue Nov 17 2:40–3pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows From Collection to Analysis: Evaluating Patient-Centric Dried Blood Microsampling Technologies for Regulated Bioanalysis Sampling Talk Tue Nov 17 5:20–5:40pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Measuring Biological Response Using RT-qPCR: A Bioanalytical Perspective on Relative Gene Expression PCR · Biomarkers
AstraZeneca Cambridge, UK
astrazeneca.com Pharma Pharmaceutical company with medicines in oncology, cardiovascular, renal and metabolic, respiratory and immunology, and rare diseases.	Talk Wed Nov 18 4:35–4:50pm Part of Workshop 7: New Approach Methodologies - NAM Bioanalysis as a Scientific Partner in NAM Development: Advancing a Bone Marrow Microphysiological System from Characterisation to Translational Implementation Sampling Talk Thu Nov 19 11:30–11:50am Part of Session 18: Connecting Metabolism, Exposure and Multi-Omics From Tissue Microenvironments to Mechanism: Deploying LMD-Omics Across Drug Exposure, Toxicity and Disease Biology LC–MS
UCB Brussels, Belgium
ucb.com Pharma Biopharmaceutical company developing medicines for immunology and neurology, including epilepsy and inflammatory diseases.	Talk Tue Nov 17 3–3:20pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows Routine use of surrogate matrix in regulated bioanalysis Sampling Talk Tue Nov 17 5–5:20pm Part of Session 9: New technologies and emerging modalities in Bioanalysis: PCR Overcoming tissue matrix interference in a droplet digital PCR analytical method for biodistribution assessment PCR
University of Hertfordshire Hatfield, UK
herts.ac.uk Universities & institutes Public university in Hatfield, UK, with schools of life and medical sciences and of pharmacy.	Talk Tue Nov 17 3:20–3:40pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows Development and Academia-to-Industry Transfer of a Patient-Centric Microsampling LC-MS/MS Assay for COPD Medication Monitoring Sampling · LC–MS
Waters Milford, Massachusetts
waters.com Instruments, reagents & software Makes liquid chromatography, mass spectrometry and lab informatics products.	Talk Tue Nov 17 3:20–3:40pm Part of Session 5: Expanding LC–MS Bioanalysis: New Modalities, Advanced Workflows and Multi-Omics Correlations between plasma concentrations of a tyrosine kinase inhibitor and its metabolites and changes in the lipid – proteome in the rat: A 3R’s & Multi-Omics Study LC–MS · Sampling